Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 13/20 | 0.64 |
| ▸ | PDE4B | Q07343 | 13/20 | 0.64 |
| ▸ | PDE4C | Q08493 | 13/20 | 0.64 |
| ▸ | PDE4D | Q08499 | 13/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 10/20 | 0.64 |
| ▸ | ADORA2B | P29275 | 8/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL316930 | 0.85 | ADORA2B (0.62) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL316171 | 0.85 | PDE4A (0.82) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL9120454 | 0.81 | ADORA2B (0.57) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL27464533 | 0.80 | PDE4A (0.66) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL21381252 | 0.80 | ADORA2A (0.82) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL316763 | 0.78 | ADORA2B (1.00) | ADORA2BBLM | |
| SCHEMBL8656014 | 0.78 | PDE4A (0.62) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL316911 | 0.77 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL11458747 | 0.77 | PDE4A (0.85) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL11458748 | 0.77 | PDE4A (0.63) | PDE4APDE4BPDE4CPDE4DADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193201-B2 | Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines | METAPROTEOMICS, LLC (US) | 2012-06-05 | — | — | US | claimed |
| US-20110172253-A1 | SYNERGISTIC ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS USING CURCUMINOIDS OR METHYLXANTHINES | METAPROTEOMICS, LLC (US) | 2011-07-14 | — | — | US | claimed |
| EP-2338481-A2 | Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines | Metaproteomics, LLC (US) | 2011-06-29 | — | — | EP | claimed |
| US-7914831-B2 | Alpha acids, isoalpha acids, reduced isoalpha acids, tetra-hydroisoalpha acids, hexa-hydroisoalpha acids, beta acids from hops; nontoxic | METAPROTEOMICS, LLC (US) | 2011-03-29 | — | — | US | claimed |
| CN-101690744-A | synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines | METAPROTEOMICS LLC | 2010-04-07 | — | — | CN | claimed |
| US-20070185213-A1 | Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines | WHITEHORSE CAPITAL ORIGINATION, LLC, AS AGENT | 2007-08-09 | — | — | US | claimed |
| CN-1946409-A | Synergistic anti-inflammatory pharmaceutical compositions and related methods of using curcuminoids or methylxanthines | METAPROTEOMICS LLC (US) | 2007-04-11 | — | — | CN | claimed |
| EP-1718312-A2 | SYNERGISTIC ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS USING CURCUMINOIDS OR METHYLXANTHINES | Metaproteomics, LLC (US) | 2006-11-08 | — | — | EP | claimed |
| WO-2005084230-A2 | SYNERGISTIC ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS USING CURCUMINOIDS OR METHYLXANTHINES | METAPROTEOMICS, LLC (US) | 2005-09-15 | — | — | WO | claimed |
| US-20050191375-A1 | Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines | WHITEHORSE CAPITAL ORIGINATION, LLC, AS AGENT | 2005-09-01 | — | — | US | claimed |
| US-9468645-B2 | Highly soluble purine bioactive compounds and compositions thereof | ENERGY BEVERAGES LLC | 2016-10-18 | — | — | US | disclosed |
| US-20160128943-A1 | CONTROLLED RELEASE CAFFEINE DOSAGE FORMS | KVK-Tech, Inc. (US) | 2016-05-12 | — | — | US | disclosed |
| US-20150238494-A1 | HIGHLY SOLUBLE PURINE BIOACTIVE COMPOUNDS AND COMPOSITIONS THEREOF | ENERGY BEVERAGES LLC | 2015-08-27 | — | — | US | disclosed |
| US-20150132440-A1 | DIPEPTIDE AND TRIPEPTIDE COMPOSITIONS AND USES | JHO INTELLECTUAL PROPERTY HOLDINGS, LLC | 2015-05-14 | — | — | US | disclosed |
| EP-1718312-B1 | Pharmaceutical compositions comprising hops extract derivatives and caffeine | METAPROTEOMICS LLC (US) | 2015-03-25 | — | — | EP | disclosed |
| US-20070185213-A1 | Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines | WHITEHORSE CAPITAL ORIGINATION, LLC, AS AGENT | 2007-08-09 | — | — | US | disclosed |
| CN-1946409-A | Synergistic anti-inflammatory pharmaceutical compositions and related methods of using curcuminoids or methylxanthines | METAPROTEOMICS LLC (US) | 2007-04-11 | — | — | CN | disclosed |
| EP-1718312-A2 | SYNERGISTIC ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS USING CURCUMINOIDS OR METHYLXANTHINES | Metaproteomics, LLC (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005084230-A2 | SYNERGISTIC ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS USING CURCUMINOIDS OR METHYLXANTHINES | METAPROTEOMICS, LLC (US) | 2005-09-15 | — | — | WO | disclosed |
| US-20050191375-A1 | Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines | WHITEHORSE CAPITAL ORIGINATION, LLC, AS AGENT | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185213-A1 | Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines | HMOX1, HMOX2, HPGDS | PDE4A 772/4885PDE4B 763/4885PDE4C 1282/4885 |
| US-20160128943-A1 | CONTROLLED RELEASE CAFFEINE DOSAGE FORMS | SLC18A1, RYR1, SLC6A2 | PDE4A 83/4885PDE4B 80/4885PDE4C 124/4885 |
| US-20110172253-A1 | SYNERGISTIC ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS USING CURCUMINOIDS OR METHYLXANTHINES | HMOX1, HMOX2, HPGDS | PDE4A 772/4885PDE4B 763/4885PDE4C 1282/4885 |
| US-20150238494-A1 | HIGHLY SOLUBLE PURINE BIOACTIVE COMPOUNDS AND COMPOSITIONS THEREOF | ADORA2A, PNP, P2RX6 | PDE4A 122/4885PDE4B 135/4885PDE4C 167/4885 |
| US-20050191375-A1 | Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines | HMOX1, HMOX2, HPGDS | PDE4A 772/4885PDE4B 763/4885PDE4C 1282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.